A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial
Maria Pearse, Carol Fraser-Browne, Ian D Davis, Gillian M Duchesne, Richard Fisher, Mark Frydenberg, Annette Haworth, Chakiath Jose, David J Joseph, Tee S Lim, John Matthews, Jeremy Millar, Mark Sidhom, Nigel A Spry, Colin I Tang, Sandra Turner, Scott G Williams, Kirsty Wiltshire, Henry H Woo, Andrew Kneebone
BJU INTERNATIONAL | WILEY-BLACKWELL | Published : 2014
OBJECTIVES: To test the hypothesis that observation with early salvage radiotherapy (SRT) is not inferior to 'standard' treatment with adjuvant RT (ART) with respect to biochemical failure in patients with pT3 disease and/or positive surgical margins (SMs) after radical prostatectomy (RP). To compare the following secondary endpoints between the two arms: patient-reported outcomes, adverse events, biochemical failure-free survival, overall survival, disease-specific survival, time to distant failure, time to local failure, cost utility analysis, quality adjusted life years and time to androgen deprivation. PATIENTS AND METHODS: The Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial i..View full abstract
Richard Fisher declares salary support via grants from the NHMRC, the Cancer Council Victoria and the New Zealand HRC. Carol Fraser-Browne declares salary support via a grant from the New Zealand HRC. The remaining authors' institutions receive grant funding from the NZ HRC, NHMRC, the CC NSW or the CC VIC.